Japan Central Nervous System (CNS) Therapeutic Market

Japan Central Nervous System (CNS) Therapeutic Market Insights Forecasts to 2035

• The Japan Central Nervous System (CNS) Therapeutic Market Size Was Estimated at USD 5460.34 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 8.78% from 2025 to 2035
• The Japan Central Nervous System (CNS) Therapeutic Market Size is Expected to Reach USD 13780 Million by 2035

According to a research report published by decision advisor & Consulting, the Japan Central Nervous System Market size is anticipated to reach USD 13780 Million by 2035, growing at a CAGR of 8.78% from 2025 to 2035. Japan Central Nervous System (CNS) Therapeutic Market is driven by older population, the growing rate of neurological and mental health conditions, and increased government efforts.

Market Overview

A Central Nervous System (CNS) therapeutic is a treatment used for problems that affect the brain and spinal cord. These treatments help manage conditions like Alzheimer’s, Parkinson’s, stroke, and other brain or mental health disorders. Since it’s hard for many medicines to reach the brain, CNS treatments often use special delivery methods such as nasal sprays, tiny particles, or gene-based approaches to work effectively. Central Nervous System (CNS) therapeutics include growing demand for treatments for neurodegenerative disorders due to an aging population, increasing use of AI and biomarkers to improve research and development, and a move toward personalized therapies and non-opioid options for pain management. Central Nervous System (CNS) drugs to work, they need to cross the blood-brain barrier (BBB). To do this, they must have the right characteristics such as being small in size, having moderate fat-solubility, and having an appropriate number of hydrogen bonds.

Governments provide funding for research into the mechanisms of CNS diseases and the development of new therapies. This includes support for academic institutions and public health bodies like the National Institutes of Health (NIH).

Report Coverage

This research report categorizes the market for the Japan Central Nervous System (CNS) Therapeutic Market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan Central Nervous System (CNS) Therapeutic Market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan Central Nervous System (CNS) Therapeutic Market.

Driving Factor

Japan Central Nervous System (CNS) therapeutic market is largely driven by its aging population and the rise in related CNS disorders, as well as strong government backing for R&D and the launch of innovative treatments. Together, these factors boost the need for new medicines and therapeutic options.

Restraining Factor

The main restrain facing Japan Central Nervous System (CNS) therapeutics market mirror global issues, including the difficulty of overcoming the blood-brain barrier (BBB), the high cost and risk involved in R&D, and the complexity of regulatory requirements.

Market segmentation

The Japan Central Nervous System (CNS) Therapeutic Market share is categorized by disease type and distribution.

By Disease Type

The Japan central nervous system (CNS) therapeutic market is segmented by disease type into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, CNS cancer, and others. Among these, the mental health is dominant in Japan central nervous system (CNS) therapeutic market due to rising public awareness, the increasing prevalence of mental health conditions such as depression and anxiety, and substantial government support and funding for related research and development.

By Distribution

The Japan central nervous system (CNS) therapeutic market is segmented by distribution into hospital pharmacy, retail pharmacy, and others. Among these, the hospital pharmacy is dominant in Japan central nervous system (CNS) therapeutic market due to the specialized expertise and intensive medical supervision necessary for managing acute and complex neurological and psychiatric conditions, hospitals and particularly hospital pharmacies retain a central role in delivering the high-value, specialized treatments central to the CNS therapeutics market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan central nervous system (CNS) therapeutic market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Otsuka Pharmaceutical Co., Ltd.
• Eisai Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Astellas Pharma Inc.
• Shionogi & Co., Ltd.
• Daiichi Sankyo Co., Ltd.
• Chugai Pharmaceutical Co., Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Sumitomo Pharma
• Meiji Seika Pharma Co., Ltd.
• NS Pharma
• Other

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In April 2024: NS Pharma, Inc. and MiNA Therapeutics formed a strategic partnership focused on rare central nervous system disorders. Nippon Shinyaku Co., the Kyoto-based parent company of NS Pharma, entered into a collaborative research agreement with MiNA Therapeutics in London to advance nucleic acid therapies for difficult-to-treat and rare CNS conditions. The NS Pharma Innovation Research Partnering (IRP) team in the United States facilitated the agreement.
• In November 2025: Takeda broadened its gene therapy manufacturing capabilities in Japan to boost viral vector production, strengthening its capacity to develop next-generation therapies, potentially including gene treatments for CNS disorders.

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035.decision advisor has segmented the Japan Central Nervous System (CNS) Therapeutic Market based on the below-mentioned segments:

Japan Central Nervous System (CNS) Therapeutic Market, By Disease Type

• Neurovascular Diseases
• CNS Trauma
• Mental Health
• Neurodegenerative Diseases
• Infectious Diseases
• CNS Cancer
• Others

Japan Central Nervous System (CNS) Therapeutic Market, By Distribution

• Hospital Pharmacy
• Retail Pharmacy
• Others

Frequently Asked Questions (FAQ’s)

Q: What is the Japan central nervous system (CNS) therapeutic market size?

A: Japan Central Nervous System (CNS) Therapeutic Market size is expected to grow from USD 5460.34 million in 2024 to USD 13780 million by 2035, growing at a CAGR of 8.78% during the forecast period 2025-2035. 

Q: What factors restrain the Japan central nervous system (CNS) therapeutic market?

A: The main restrain facing Japan Central Nervous System (CNS) therapeutics market mirror global issues, including the difficulty of overcoming the blood-brain barrier (BBB), the high cost and risk involved in R&D, and the complexity of regulatory requirements.

Q: Who are the target audiences for this market report?

A: The report targets market players, investors, end-users, government authorities, consulting and research firms, venture capitalists, and value-added resellers (VARs).

Q: Who are the target audiences for Japan central nervous system (CNS) therapeutic market report?

A: The report targets market players, Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Sumitomo Pharma, Meiji Seika Pharma Co., Ltd., NS Pharma, and Other.